Neumora Therapeutics Files 8-K
Ticker: NMRA · Form: 8-K · Filed: Oct 27, 2025 · CIK: 1885522
| Field | Detail |
|---|---|
| Company | Neumora Therapeutics, INC. (NMRA) |
| Form Type | 8-K |
| Filed Date | Oct 27, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: filing, corporate-update
Related Tickers: NMRA
TL;DR
Neumora filed an 8-K on 10/27/25. Nothing major disclosed yet.
AI Summary
Neumora Therapeutics, Inc. filed an 8-K on October 27, 2025, reporting other events and financial statements. The company, formerly known as RBNC Therapeutics, Inc. until September 29, 2021, is incorporated in Delaware and headquartered in Watertown, Massachusetts.
Why It Matters
This filing indicates Neumora Therapeutics, Inc. is providing updates on its corporate activities and financial status to the SEC.
Risk Assessment
Risk Level: low — The filing is a routine 8-K for 'Other Events' and 'Financial Statements and Exhibits' without specific material disclosures of new risks.
Key Numbers
- 001-41802 — SEC File Number (Identifies the company's filing with the SEC.)
- 844367680 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Neumora Therapeutics, Inc. (company) — Registrant
- RBNC Therapeutics, Inc. (company) — Former Name
- October 27, 2025 (date) — Date of Report
- September 29, 2021 (date) — Date of Name Change
- Delaware (jurisdiction) — State of Incorporation
- Watertown, Massachusetts (location) — Principal Executive Offices
FAQ
What specific 'Other Events' are being reported by Neumora Therapeutics, Inc. in this 8-K?
The provided text does not detail the specific 'Other Events' beyond listing it as an item information category.
What is the significance of filing 'Financial Statements and Exhibits' on this date?
This indicates that Neumora Therapeutics, Inc. is providing updated financial information and exhibits as required by the SEC, though the specifics are not detailed in this excerpt.
When did Neumora Therapeutics, Inc. change its name from RBNC Therapeutics, Inc.?
The company changed its name from RBNC Therapeutics, Inc. on September 29, 2021.
Where are Neumora Therapeutics, Inc.'s principal executive offices located?
The principal executive offices are located at 260 Arsenal Place, Suite 1, Watertown, Massachusetts, 02472.
What is the SIC code for Neumora Therapeutics, Inc.?
The Standard Industrial Classification (SIC) code for Neumora Therapeutics, Inc. is 2836, which corresponds to Biological Products (No Diagnostic Substances).
Filing Stats: 462 words · 2 min read · ~2 pages · Grade level 12.3 · Accepted 2025-10-27 06:34:33
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share NMRA The Nasdaq
Filing Documents
- nmra-20251027.htm (8-K) — 44KB
- nmra-ex99_1.htm (EX-99.1) — 21KB
- img49001591_0.jpg (GRAPHIC) — 26KB
- 0001193125-25-250656.txt ( ) — 207KB
- nmra-20251027.xsd (EX-101.SCH) — 23KB
- nmra-20251027_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events. On October 27, 2025, Neumora Therapeutics, Inc. (the "Company") issued a press release announcing positive preclinical data for NMRA-215, a potentially best-in-class, highly brain-penetrant, oral NLRP3 inhibitor from three diet-induced obesity (DIO) mouse studies. In the studies, NMRA-215 demonstrated class-leading weight loss of up to 19% as a monotherapy with semaglutide-like induction and 26% in combination with high doses of semaglutide. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. Exhibit Number Description 99.1 Press Release dated October 27, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NEUMORA THERAPEUTICS, INC. Date: October 27, 2025 By: /s/ Michael Milligan Michael Milligan Chief Financial Officer